Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONO-4578 Monotherapy and Combination With ONO-4538 in Advanced or Metastatic Solid Tumors
NCT03155061Phase 1Active, not recruiting
- Sponsor
- Ono Pharmaceutical
- Start
- Apr 2017
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONO-4578 in solid tumor, gastric cancer (GC) and colorectal cancer (CRC) (4 arms), sponsored by Ono Pharmaceutical. Primary endpoint: Evaluation of safety (adverse events, clinical laboratory tests, 12-lead ECG, chest X-ray, ECOG PS) at 1 year. Started Apr 2017; status: active, not recruiting.
02
Drugs
ONO-4578
03
Conditions
solid tumorgastric cancer (GC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03155061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03155061.